Dacarbazine

Generic Name: Dacarbazine

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₀N_₆O

CAS Number: 4342-03-4

Unique Ingredient Identifier: 7GR28W0FJI

Background: An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.

Indication: For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.

Associated Conditions: Advanced Pancreatic Neuroendocrine Tumors (pNET), Advanced Soft Tissue Sarcoma, Hodgkin's Lymphoma, Metastatic Melanoma, Pheochromocytoma, Advanced Medullary thyroid cancer

Associated Therapies: -

Clinical Trials

Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above

Phase 2

Recruiting

Conditions: Classical Hodgkin Lymphoma

Interventions: Drug: Pembrolizumab
Drug: Doxorubicin
Drug: Vinblastine
Drug: Dacarbazine
Drug: Brentuximab vedotin

First Posted Date: 2022-06-03

Last Posted Date: 2024-07-03

Lead Sponsor: University of Virginia

Target Recruit Count: 44

Registration Number: NCT05404945

Locations: 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

Phase 2

Active, not recruiting

Conditions: Leiomyosarcoma

Interventions: Drug: Unesbulin
Other: Placebo
Drug: Dacarbazine

First Posted Date: 2022-03-08

Last Posted Date: 2024-06-21

Lead Sponsor: PTC Therapeutics

Target Recruit Count: 360

Registration Number: NCT05269355

Locations: 🇺🇸
University of California, Los Angeles (UCLA) - Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸
The Ohio State University (OSU), Columbus, Ohio, United States

and more 51 locations

Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

Phase 2

Completed

Conditions: Classical Hodgkin Lymphoma

Interventions: Biological: Pembrolizumab
Drug: Doxorubicin
Drug: Vinblastine
Drug: Dacarbazine
Drug: Bleomycin
Drug: Etoposide
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Procarbazine
Drug: Prednisone

First Posted Date: 2021-08-17

Last Posted Date: 2024-11-20

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 146

Registration Number: NCT05008224

Locations: 🇺🇸
Stanford Cancer Center ( Site 0023), Palo Alto, California, United States
🇺🇸
Northwestern Memorial Hospital ( Site 0002), Chicago, Illinois, United States
🇺🇸
Texas Oncology-Plano East ( Site 0020), Plano, Texas, United States

and more 45 locations

Efficacy and Safety of L19TNF in Previously Treated Patients With Advanced Stage or Metastatic Soft-tissue Sarcoma

Phase 2

Recruiting

Conditions: Soft Tissue Sarcoma

Interventions: Drug: Dacarbazine
Drug: onfekafusp alfa

First Posted Date: 2021-02-01

Last Posted Date: 2024-04-08

Lead Sponsor: Philogen S.p.A.

Target Recruit Count: 98

Registration Number: NCT04733183

Locations: 🇫🇷
Institut Bergonié, Bordeaux, France
🇵🇱
Maria Sklodowska Curie National Research Institute of Oncology, Warsaw, Poland
🇫🇷
Institut Gustave Roussy, Villejuif, France

and more 20 locations

CytoreductiveSurgery & HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma

Phase 2

Recruiting

Conditions: LMS - Leiomyosarcoma
Uterine Leiomyosarcoma

Interventions: Drug: Gemcitabine
Drug: Dacarbazine
Procedure: Cytoreductive Surgery
Behavioral: Functional Assessment of Cancer Therapy (FACT) G questionnaire
Procedure: Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Scan
Drug: Gadolinium

First Posted Date: 2021-01-27

Last Posted Date: 2024-03-05

Lead Sponsor: Kristen Ganjoo

Target Recruit Count: 25

Registration Number: NCT04727242

Locations: 🇺🇸
Stanford University, Stanford, California, United States

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Phase 3

Recruiting

Conditions: Hodgkin Lymphoma

Interventions: Radiation: Involved site radiotherapy
Drug: Doxorubicin
Drug: Bleomycin
Drug: Brentuximab vedotin
Drug: Vinblastine
Drug: Dacarbazine
Drug: Haematopoietic growth factor

First Posted Date: 2020-12-28

Last Posted Date: 2024-10-30

Lead Sponsor: University College, London

Target Recruit Count: 1042

Registration Number: NCT04685616

Locations: 🇳🇱
Reinier de Graafweg 3-11 - Postbus 5011 - 2625 AD Delft, Delft, Netherlands
🇬🇧
Colchester Hospital, ESNEFT, Colchester, United Kingdom
🇬🇧
The Clatterbridge Cancer Centre NHSFT, 65 Pembroke Place, Liverpool, United Kingdom

and more 38 locations

First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)

Phase 3

Recruiting

Conditions: Hodgkin Lymphoma, Adult

Interventions: Drug: Doxorubicin
Drug: Bleomycin
Drug: Vinblastine
Drug: Cyclophosphamide
Drug: Dacarbazine
Drug: Etoposide
Drug: Vincristine
Drug: Dexamethasone

First Posted Date: 2020-11-20

Last Posted Date: 2022-11-01

Lead Sponsor: State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia

Target Recruit Count: 300

Registration Number: NCT04638790

Locations: 🇮🇳
Tata Memorial Hospital, Mumbai, OPD-81 Main building, Dr. E Borges Road, Parel 400012, India
🇷🇺
The Federal Budget-Funded Institution National Medical Surgical Center named after N. I. Pirogov of the Ministry of health of the Russian Federation, Moscow, Russian Federation

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

Phase 3

Recruiting

Conditions: High-Risk Neuroblastoma
Patient With Insufficient Response Chemoimmunotherapy

Interventions: Radiation: Radiotherapy
Drug: Vincristine
Drug: Busulfan
Drug: Dinutuximab Beta
Drug: Carboplatin
Drug: Melphalan
Drug: Etoposide
Drug: Thiotepa
Drug: Vindesine
Drug: Dacarbazine
Drug: Ifosfamide
Drug: Doxorubicin
Drug: Cisplatin
Drug: Temozolomide 100 MG
Drug: Irinotecan
Drug: Cyclophosphamid

First Posted Date: 2020-01-09

Last Posted Date: 2024-05-16

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 800

Registration Number: NCT04221035

Locations: 🇬🇷
University General Hospital of Thessaloniki "AHEPA", Thessaloniki, Greece
🇬🇷
Children's General Hospital "AGHIA SOFIA", Athens, Greece
🇮🇹
instituto Giannina Gaslini genova, Genova, Italy

and more 134 locations

Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma

Phase 2

Recruiting

Conditions: Classical Hodgkin Lymphoma

Interventions: Drug: Camrelizumab
Drug: Epirubicin
Drug: Vincristine
Drug: Dacarbazine

First Posted Date: 2019-08-26

Last Posted Date: 2024-05-07

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 60

Registration Number: NCT04067037

Locations: 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

Phase 3

Active, not recruiting

Conditions: Lymphocyte-Rich Classic Hodgkin Lymphoma
Ann Arbor Stage III Hodgkin Lymphoma
Classic Hodgkin Lymphoma
Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma
Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma
Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma
Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma
Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma
Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma
Ann Arbor Stage IV Hodgkin Lymphoma

Interventions: Procedure: Biospecimen Collection
Drug: Brentuximab Vedotin
Procedure: Computed Tomography
Drug: Dacarbazine
Drug: Doxorubicin Hydrochloride
Biological: Filgrastim
Procedure: Magnetic Resonance Imaging
Biological: Nivolumab
Biological: Pegfilgrastim
Procedure: Positron Emission Tomography
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Radiation: Radiation Therapy
Drug: Vinblastine Sulfate

First Posted Date: 2019-04-09

Last Posted Date: 2024-11-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 995

Registration Number: NCT03907488

Locations: 🇺🇸
Corewell Health Beaumont Troy Hospital, Troy, Michigan, United States
🇺🇸
Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan, United States
🇺🇸
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti, Michigan, United States

and more 731 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy